On Sept. 2, 2022, Novavax announced that the World Health Organization (WHO) had approved a variation to allow SK bioscience to manufacture and supply the active substance in the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine.

This variation approval enabled Novavax to manufacture product for countries who recognize WHO exceptional use license from two major vaccine suppliers – SK bioscience and the Serum Institute of India. This approval was the first Coalition for Epidemic Preparedness Innovations (CEPI)-funded network production for Novavax.